Immunomedics blasted after UCB lupus PhIIIs fail

UCB says that its two Phase III trials for their lupus drug epratuzumab failed. The developer said that neither of the two doses used in the identical, late-stage trials proved statistically superior to a placebo. The CD-22 targeting antibody was in-licensed from Immunomedics ($IMMU), which was hammered hard after the news hit. Morris Plains, NJ-based Immunomedics' shares were down 42% in early trading Tuesday. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.